99994 Item Items
Warning: Last items in stock!
By buying this product you can collect up to 9 loyalty points. Your cart will total 9 points that can be converted into a voucher of 1,80€.
Like nandrolone, methenolone is very mild on the system. Probably the reason why both are strongly favored as base compounds in stacks. Methenolone has no estrogenic side-effects whatsoever, on account of its structure. Its effects on the cholesterol levels are barely noticeable. In doses of 200 mg or less (injectable) blood pressure is rarely, if at all, altered. As for hepatoxicity, long-term use will of course increase liver values but gradually and only slightly. The injections of course, since they only pass the liver once, have roughly half the liver-toxic effects of the tabs. The low liver-toxicity is accounted for that the bio-availability of methenolone is carried by a 1-methyl-group, which lessens the need for a carrier attachment such as a 17-alpha-akylated group, the main culprit in steroid-related liver afflictions.
The strangest thing however, taking into account that Primo is still a DHT (or rather DHB) derivative, is that it is quite easy on the system androgenically as well. Women use methenolone often, usually the tabs, and find little virilisation symptoms in short term use of methenolone. Long-term use may induce some acne and a deepening of the voice however. Methenolone is also not overly suppressive of the HPT axis (endocrinal axis for the production of natural testosterone). These are both the result of DHB's 1,2-double bond, which, analog to the parent structure boldenone, reduces the androgenic binding by 50% as opposed to DHT.
No customer reviews for the moment.